INM

#4945
InMed Pharmaceuticals Inc. - Common Shares
1.3 5 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.35
1.35
Jahresspanne
0.58
2.50
Tagesänderung
-2.17%
Monatliche Änderung
-8.16%
6 month change
+60.71%
Jahresänderung
-36.92%
Vorheriger Schlusskurs
1.3 8
Open
1.3 5
Tief
1.3 5
Hoch
1.3 5
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Inmed Pharmaceuticals Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Inmed Pharmaceuticals Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Inmed Pharmaceuticals Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Inmed Pharmaceuticals Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Inmed Pharmaceuticals Inc. current report, Q1 FY2026
8-K

Inmed Pharmaceuticals Inc. current report, Q3 FY2025

Full document

Business Context and Reporting Period

Company: Inmed Pharmaceuticals Inc. (INM)
Filing Type: Form 8-K (Current Report)
Date of Report: September 23, 2025
Reporting Period Covered: Fiscal Year ended June 30, 2025

This filing serves as a Regulation FD disclosure announcing the Company's financial results for the fiscal year ended June 30, 2025. It also includes a business update regarding pharmaceutical drug development programs and the commercial segment of its wholly-owned subsidiary, BayMedica, LLC.

Key Financial Metrics

The provided text is a cover page and index for the 8-K filing. It references the announcement of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced Exhibit 99.1 (News release), which is not included in the input text.

Material Changes

The filing text does not provide specific comparative data or details on material changes versus the prior comparable period. It only confirms that an update on financial results and business operations was issued.

Guidance, Outlook, and Management Commentary

  • Business Update: Management provided updates on pharmaceutical drug development programs.
  • Commercial Segment: Updates were provided for BayMedica, LLC, the Company's wholly-owned subsidiary.
  • Legal Status of Information: The information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Verify the specific financial figures (revenue, net loss, cash position) in the full text of Exhibit 99.1 (News release dated September 23, 2025).
  • Review the detailed progress of the pharmaceutical drug development programs mentioned in the business update.
  • Assess the commercial performance metrics for the BayMedica, LLC subsidiary.
  • Confirm the Company's status as an emerging growth company (indicated as "Yes" in the filing).

Nachrichten